Zydus Therapeutics Inc.

Zydus Therapeutics Inc. is a clinical-stage, specialty-focused biopharmaceutical company based in Pennington, New Jersey, in the United States. It operates as a subsidiary of Zydus Lifesciences, the Indian pharmaceutical group, and functions as the group's US-based clinical development arm for specialty and rare-disease programs. The company describes its mission as developing transformative treatments to transform lives, beginning with rare and serious liver diseases. Unlike a commercial-stage pharmaceutical manufacturer, Zydus Therapeutics is positioned as a clinical-stage developer. Its public communications emphasize a pipeline that is currently advancing through late-stage clinical trials, with patient enrollment under way in two late-stage studies addressing rare and serious liver diseases. The company frames its purpose around empowering people with the freedom to live healthier and more fulfilling lives by unlocking new possibilities in life sciences and providing quality healthcare solutions. As a subsidiary of Zydus Lifesciences, Zydus Therapeutics draws on the parent group's substantial research, development and manufacturing infrastructure. According to the company, its pipeline is fueled by approximately 1,300 researchers working with cutting-edge technologies to discover new medicines, and its manufacturing network includes more than 30 sites with capabilities spanning active pharmaceutical ingredient (API) development through tablet and biologics manufacturing. This access to integrated R&D and manufacturing capability is a central element of the subsidiary's positioning within the broader Zydus group. The company's leadership team includes Chris Cann as Chief Operating Officer and Dr. Deven Parmar as Chief Medical Officer and Head of Clinical Research & Development. Cann oversees all aspects of the company's commercialization strategy and execution and previously served as Vice President, Global Strategy at Intercept Pharmaceuticals, with earlier business leadership roles at Sanofi, AstraZeneca, Bristol-Myers Squibb and Merck. Dr. Parmar is a clinical pharmacologist with more than 25 years of experience in drug development and more than 100 scientific presentations and publications. Zydus Therapeutics represents the US specialty and rare-disease face of the Zydus Lifesciences group, combining the resources of a large generics and specialty pharmaceutical organization with the focus of a dedicated clinical-stage biotechnology company. Its activities center on advancing novel medicines for liver disease through late-stage clinical development.

Zydus Therapeutics Inc. is the United States-based, clinical-stage specialty biopharmaceutical subsidiary of Zydus Lifesciences, the Indian pharmaceutical group. The company is headquartered in Pennington, New Jersey, and positions itself as a developer of transformative treatments, beginning with rare and serious liver diseases. The subsidiary's history is closely tied to the strategic evolution of its parent, Zydus Lifesciences. Zydus Lifesciences is one of India's leading pharmaceutical companies, with a global footprint spanning generics, specialty medicines, consumer healthcare, and biologics. As the group expanded its specialty and rare-disease ambitions, it established a dedicated US clinical development presence to advance novel medicines through late-stage trials. Zydus Therapeutics Inc. serves that role, operating as the group's US-based specialty-focused clinical-stage entity. From its inception, Zydus Therapeutics has been structured to leverage the parent group's integrated research, development and manufacturing capabilities. According to the company, its pipeline is fueled by approximately 1,300 researchers working with cutting-edge technologies, and its manufacturing network includes more than 30 sites with capabilities ranging from active pharmaceutical ingredient (API) development through tablet and biologics manufacturing. This access to group-wide resources allows the subsidiary to conduct clinical development while drawing on the scale and infrastructure of a large pharmaceutical organization. The company's therapeutic focus is on rare and serious liver diseases. Its public communications state that its teams are working to develop novel medicines and are currently enrolling patients in two late-stage clinical trials addressing rare and serious liver diseases. This focus places Zydus Therapeutics in the specialty and rare-disease segment of the pharmaceutical industry, where development programs target conditions with significant unmet medical need. Leadership of the US subsidiary includes Chris Cann as Chief Operating Officer and Dr. Deven Parmar as Chief Medical Officer and Head of Clinical Research & Development. Cann brings commercialization and global strategy experience from Intercept Pharmaceuticals, Sanofi, AstraZeneca, Bristol-Myers Squibb and Merck. Dr. Parmar is a clinical pharmacologist with more than 25 years of drug development experience and more than 100 scientific presentations and publications, and is a member of the ICH M11 working group. As of its public communications, Zydus Therapeutics remains a clinical-stage company, with its near-term milestones centered on advancing its late-stage liver disease programs. It operates as part of the Zydus Lifesciences group, which provides the research, development and manufacturing foundation on which the subsidiary's pipeline is built.

• Zydus Therapeutics Inc. operates as a US-based clinical-stage specialty biopharmaceutical subsidiary of Zydus Lifesciences, headquartered in Pennington, New Jersey.

• The company reports that it is enrolling patients in two late-stage clinical trials addressing rare and serious liver diseases.

Clinical-stage, specialty-focused biopharmaceutical subsidiary of Zydus Lifesciences focused on transformative treatments for rare and serious liver diseases.

• Clinical-stage drug candidates for rare and serious liver diseases

  The company's pipeline focuses on novel medicines for rare and serious liver diseases, with two late-stage clinical trials currently enrolling patients.

1. 1Home - Zydus Therapeuticszydustx.com
2. 2About Us - Zydus Therapeuticszydustx.com
3. 3Zydus Therapeutics Inc. (United States) - Wikidatawikidata.org